Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Long-Acting Insulin Offerings Could Derail Lantus Franchise

Executive Summary

Companies presented data at ADA that could give patients options other than Lantus, but Sanofi is fighting back with a strategy to retain them.

You may also be interested in...



2013 Diabetes NMEs Span Classes, But Safety Is A Review Issue For All

The repercussions of FDA’s 2008 guidance on cardiovascular risk evaluation in diabetes trials are still being felt in reviews of new agents. CV concerns earned Novo Nordisk’s long-acting basal insulin a “complete response” letter. Pending applications include two GLP-1 agonists and a possible first-in-class SGLT-2 inhibitor, and safety is a major review issue for all of them.

Lilly Puts Faith In Late-Stage Assets In Hopes Of Profit Growth In 2014

Lilly is making major bets on the oncology and diabetes drugs in its late-stage pipeline in hopes that these assets will fill the hole left by Zyprexa, and soon Cymbalta.

2013 Diabetes NMEs Span Classes, But Safety Is A Review Issue For All

The repercussions of FDA’s 2008 guidance on cardiovascular risk evaluation in diabetes trials are still being felt in reviews of new agents. Pending applications include two GLP-1 agonists, the third review of a DPP-IV inhibitor, a possible first-in-class SGLT-2 inhibitor and a long-acting basal insulin, and safety is a major review issue for all of them.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel